
Combinations therapy by rational design
Serinus Biosciences is an AI drug discovery company targeting the convergence of cancer signaling. Protein-protein interactions (PPIs) form the physical core of signaling networks that drive disease emergence and progression. Our Pep-to-Mol platform leverages recent advances in protein structure prediction and our proprietary PPI energetics database to convert any peptide binder, including the natural binding protein itself, to a potent small molecule inhibitor. We have recently established a number of hit series for a previously undruggable PPI targets in under 4 months of development. Our lead program is a first-in-class PPI target with a market opportunity of >$20B (in the US alone) across a diverse set of lethal solid tumors. We operate at the cutting edge of AI, biology, and drug design, to develop novel treatments for patients in need. Founded by MIT graduates, Serinus Biosciences is supported by leading investors, including Illumina Ventures, Vertex Ventures, Y-Combinator, and Merck Digital Science Studios. Our work has been published in leading journals, including Science, Cell, Nature Biotechnology, and Cancer Cell. Our advisory board includes world-renowned researchers from the Broad Institute, Dana-Farber Cancer Institute, and UCSD. Join our team to help shape the next generation of cancer treatments!
We are looking to add a new member to our computational team. In this role, you will be at the intersection of cutting-edge machine learning, computational chemistry, and drug discovery. You'll work directly on our Pep-to-Mol platform alongside our experienced drug discovery team to transform the landscape of therapeutics, turning previously intractable PPI targets into viable drug candidates. The ideal candidate likely has a scientific background in the life and/or hard sciences, is deeply excited by the recent breakthroughs in biomolecular structure prediction (e.g. AlphaFold) and other approaches to understand and exploit biology using massive datasets, and enjoys bending computers to their will.
Your key responsibilities will include:
We are a tight-knit and motivated team at the cutting edge of what we do. You will learn a ton and be trusted with extreme ownership. When we succeed, patients benefit!
Serinus Biosciences is redefining precision in cancer therapeutics. We design models to determine how molecules function inside each tumor cell. Through our knowledge-primed AI engine, we integrate computational biology and functional genomics to uncover the molecular landscape of treatment response or resistance. Our technology enables the development of drugs that work across a wide range of patient populations, override resistance mechanisms, and enable combinations by design.
Founded by MIT PhDs and supported by Y-Combinator, Serinus is a seed-stage TechBio company backed by top investors. Serinus’s scientific advisory includes top academics from the Broad Institute, Dana-Farber, and UCSD. Join our core founding team to help us shape the company’s vision, strategy, and technology.